You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCyclosporine
Accession NumberDB00091  (BTD00003, BIOD00003)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionA cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. Cyclosporine is produced as a metabolite by the fungus species Cordyceps militaris. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Structure
Thumb
Synonyms
Ciclosporin
Ciclosporina
Ciclosporine
Ciclosporinum
CsA
CyA
Cyclosporin
Cyclosporin A
External Identifiers
  • Antibiotic S 7481F1
  • Antibiotic S-7481F1
  • NSC-290193
  • SANG-35
  • SDZ-OXL-400
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyclosporineCapsule25 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
NeoralSolution100 mg/mLOralNovartis Pharmaceuticals Corporation1995-07-14Not applicableUs
NeoralCapsule, liquid filled25 mg/1OralNovartis Pharmaceuticals Corporation1995-07-14Not applicableUs
NeoralCapsule, liquid filled25 mg/1OralCardinal Health1995-07-14Not applicableUs
NeoralCapsule, liquid filled100 mg/1OralNovartis Pharmaceuticals Corporation1995-07-14Not applicableUs
Neoral 100mgCapsule100 mgOralNovartis Pharmaceuticals Canada Inc1995-12-31Not applicableCanada
Neoral 10mgCapsule10 mgOralNovartis Pharmaceuticals Canada Inc1998-10-02Not applicableCanada
Neoral 25mgCapsule25 mgOralNovartis Pharmaceuticals Canada Inc1995-12-31Not applicableCanada
Neoral 50mgCapsule50 mgOralNovartis Pharmaceuticals Canada Inc1995-12-31Not applicableCanada
Neoral Oral Solution 100mg/mlSolution100 mgOralNovartis Pharmaceuticals Canada Inc1995-12-31Not applicableCanada
RestasisEmulsion.5 mg/mLOphthalmicAllergan, Inc.2003-04-01Not applicableUs
RestasisEmulsion0.05 %OphthalmicAllergan Inc2010-09-29Not applicableCanada
RestasisEmulsion.5 mg/mLOphthalmicPhysicians Total Care, Inc.2009-03-27Not applicableUs
RestasisEmulsion.5 mg/mLOphthalmicA S Medication Solutions2003-04-01Not applicableUs
Restasis MultidoseEmulsion.5 mg/mLOphthalmicAllergan, Inc.2016-11-10Not applicableUs
SandimmuneCapsule, liquid filled100 mg/1OralNovartis Pharmaceuticals Corporation1990-03-02Not applicableUs
SandimmuneInjection50 mg/mLIntravenousNovartis Pharmaceuticals Corporation1983-11-14Not applicableUs
SandimmuneSolution100 mg/mLOralNovartis Pharmaceuticals Corporation1983-11-14Not applicableUs
SandimmuneCapsule, liquid filled25 mg/1OralNovartis Pharmaceuticals Corporation1990-03-02Not applicableUs
Sandimmune Cap 50mgCapsule50 mgOralSandoz Canada Inc1991-12-311996-11-14Canada
Sandimmune IV 50mg/mlLiquid50 mgIntravenousNovartis Pharmaceuticals Canada Inc1984-12-31Not applicableCanada
Sandimmune Oral Sol 100mg/mlLiquid100 mgOralSandoz Canada Inc1984-12-311997-04-15Canada
Sandimmune Soft Gelatin Cap 100mgCapsule100 mgOralSandoz Canada Inc1988-12-311997-04-15Canada
Sandimmune Soft Gelatine Cap 25mgCapsule25 mgOralSandoz Canada Inc1988-12-311997-04-15Canada
Sandoz CyclosporineCapsule100 mgOralSandoz Canada Incorporated2001-12-27Not applicableCanada
Sandoz CyclosporineCapsule25 mgOralSandoz Canada Incorporated2005-05-16Not applicableCanada
Sandoz CyclosporineCapsule50 mgOralSandoz Canada Incorporated2006-10-18Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cyclosporine Oral SolutionSolution100 mgOralApotex Inc2002-07-30Not applicableCanada
CyclosporineCapsule, liquid filled25 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
CyclosporineSolution100 mg/mLOralIVAX Pharmaceuticals, Inc.2005-03-29Not applicableUs
CyclosporineCapsule, liquid filled100 mg/1OralPhysicians Total Care, Inc.2011-02-10Not applicableUs
CyclosporineCapsule, liquid filled25 mg/1OralActavis Pharma, Inc.2008-12-01Not applicableUs
CyclosporineSolution100 mg/mLOralMorton Grove Pharmaceuticals, Inc.2005-02-09Not applicableUs
CyclosporineCapsule25 mg/1OralEon Labs, Inc.2000-01-13Not applicableUs
CyclosporineCapsule, liquid filled100 mg/1OralAmerican Health Packaging2015-03-30Not applicableUs
CyclosporineCapsule, liquid filled25 mg/1OralMayne Pharma Inc.2016-07-18Not applicableUs
CyclosporineCapsule, liquid filled100 mg/1OralActavis Pharma, Inc.2008-12-01Not applicableUs
CyclosporineCapsule, gelatin coated25 mg/1OralApotex Corp.2002-05-29Not applicableUs
CyclosporineCapsule100 mg/1OralEon Labs, Inc.2000-01-13Not applicableUs
CyclosporineCapsule100 mg/1OralAmerican Health Packaging2009-12-112015-12-29Us
CyclosporineCapsule, liquid filled100 mg/1OralMayne Pharma Inc.2016-07-18Not applicableUs
CyclosporineSolution100 mg/mLOralActavis Pharma, Inc.2008-12-01Not applicableUs
CyclosporineCapsule, gelatin coated100 mg/1OralApotex Corp.2002-05-29Not applicableUs
CyclosporineInjection, solution50 mg/mLIntravenousPerrigo Company2003-10-07Not applicableUs
CyclosporineCapsule, liquid filled100 mg/1OralCardinal Health2010-09-01Not applicableUs
CyclosporineCapsule, liquid filled100 mg/1OralPhysicians Total Care, Inc.2006-02-10Not applicableUs
Cyclosporine ModifiedCapsule, liquid filled25 mg/1OralIVAX Pharmaceuticals, Inc.2005-03-29Not applicableUs
Cyclosporine ModifiedCapsule, liquid filled25 mg/1OralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
Cyclosporine ModifiedCapsule, liquid filled50 mg/1OralIVAX Pharmaceuticals, Inc.2005-04-28Not applicableUs
Cyclosporine ModifiedCapsule, liquid filled50 mg/1OralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
Cyclosporine ModifiedCapsule, liquid filled100 mg/1OralIVAX Pharmaceuticals, Inc.2005-03-29Not applicableUs
Cyclosporine ModifiedCapsule, liquid filled100 mg/1OralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
GengrafCapsule50 mg/1OralAbb Vie Inc.2016-06-20Not applicableUs
GengrafSolution100 mg/mLOralAbb Vie Inc.2010-05-25Not applicableUs
GengrafCapsule25 mg/1OralAbb Vie Inc.2010-05-24Not applicableUs
GengrafCapsule100 mg/1OralCardinal Health2010-05-24Not applicableUs
GengrafCapsule100 mg/1OralAbb Vie Inc.2010-05-24Not applicableUs
GengrafCapsule25 mg/1OralCardinal Health2010-05-24Not applicableUs
GengrafCapsule25 mg/1OralAbb Vie Inc.2010-05-24Not applicableUs
GengrafCapsule100 mg/1OralAbb Vie Inc.2010-05-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SangcyaNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII83HN0GTJ6D
CAS number59865-13-3
WeightAverage: 1202.635
Monoisotopic: 1201.841368058
Chemical FormulaC62H111N11O12
InChI KeyPMATZTZNYRCHOR-CGLBZJNRSA-N
InChI
InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
IUPAC Name
SMILES
CC[C@@H]1NC(=O)[[email protected]]([[email protected]](O)[[email protected]](C)C\C=C\C)N(C)C(=O)[[email protected]](C(C)C)N(C)C(=O)[[email protected]](CC(C)C)N(C)C(=O)[[email protected]](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[[email protected]](C)NC(=O)[[email protected]](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[[email protected]](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Pharmacology
IndicationFor treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis.
Structured Indications
PharmacodynamicsUsed in immunosuppression for prophylactic treatment of organ transplants, cyclosporine exerts specific and reversible inhibition of immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited. The T1-helper cell is the main target, although the T1-suppressor cell may also be suppressed. Sandimmune (cyclosporine) also inhibits lymphokine production and release including interleukin-2.
Mechanism of actionCyclosporine binds to cyclophilin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine also inhibits lymphokine production and interleukin release. In ophthalmic applications, the precise mechanism of action is not known. Cyclosporine emulsion is thought to act as a partial immunomodulator in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
TargetKindPharmacological actionActionsOrganismUniProt ID
Calcium signal-modulating cyclophilin ligandProteinyes
binder
HumanP49069 details
Calcineurin subunit B type 2Proteinyes
inhibitor
HumanQ96LZ3 details
Peptidyl-prolyl cis-trans isomerase AProteinunknownNot AvailableHumanP62937 details
Peptidyl-prolyl cis-trans isomerase F, mitochondrialProteinunknown
binder
HumanP30405 details
Related Articles
AbsorptionThe absorption of cyclosporine from the gastrointestinal tract is incomplete and variable. The extent of absorption is dependent on the individual patient, the patient population, and the formulation. The absolute bioavailability of cyclosproine administered as Sandimmune® is dependent on the patient population, estimated to be less than 10% in liver transplant patients and as great as 89% in some renal transplant patients. Compared to an intravenous infusion, the absolute bioavailability of the oral solution is approximately 30% based upon the results in 2 patients. The cyclosporine capsules and oral solution are bioequivalent. The time of peak blood concentrations (Tmax) following oral administration of cyclosporine [modified] ranged from 1.5 - 2.0 hours.
Volume of distribution

The steady state volume of distribution during intravenous dosing has been reported as 3 to 5 L/kg in solid organ transplant recipients. Cyclosporine is excreted in human milk.

Protein bindingIn the plasma, approximately 90% is bound to proteins, primarily lipoproteins. In blood, the distribution is concentration dependent. Approximately 33% to 47% is in plasma, 4% to 9% in lymphocytes, 5% to 12% in granulocytes, and 41% to 58% in erythrocytes.
Metabolism

Hepatic, extensively metabolized by the cytochrome P450 3A enzyme system in the liver. It is also metabolized in the gastrointestinal tract and kidney to a lesser degree. The metabolites are significantly less potent than the parent compound. The major metabolites (M1, M9, and M4N) result from oxidation at the 1-beta, 9-gamma, and 4-N-demethylated positions, respectively.

SubstrateEnzymesProduct
Cyclosporine
Metabolite AM1Details
Route of eliminationElimination is primarily biliary with only 6% of the dose (parent drug and metabolites) excreted in the urine. Only 0.1% of the dose is excreted in the urine as unchanged drug.
Half lifeBiphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.
Clearance

Following intravenous administration, the blood clearance of cyclosporine (assay: HPLC) is approximately 5 to 7 mL/min/kg in adult recipients of renal or liver allografts. Blood cyclosporine clearance appears to be slightly slower in cardiac transplant patients. The following are clearance parameters (CL/F) for select patient populations:

  • 593 ± 204 mL/min [De novo renal transplant patients, 597±174 mg/day]
  • 492 ± 140 mL/min [Stable renal transplant patients, 344±122 mg/day]
  • 577 ± 309 mL/min [De novo liver transplant, 458±190 mg/day]
  • 613 ± 196 mL/min [De novo rheumatoid arthritis, 182±55.6 mg/day]
  • 723 ± 186 mL/min [De novo psoriasis, 189±69.8 mg/day]
  • 285 ± 94 mL/min [Stable Liver Transplant, Age 2 – 8, Dosed T.I.D 101±25 mg/day]
  • 378 ± 80 mL/min [Stable Liver Transplant, Age 8 – 15, Dosed B.I.D 188±55 mg/day]
  • 171 mL/min [Stable liver transplant, Age 3, Dosed B.I.D 120 mg/day]
  • 328 ± 121 mL/min [Stable liver transplant, Age 8 – 15, Dosed B.I.D 158±55 mg/day]
  • 418 ± 143 mL/min [Stable renal transplant, Age 7 – 15, Dosed B.I.D 328±83 mg/day]
ToxicityThe oral LD50 is 2329 mg/kg in mice, 1480 mg/kg in rats, and > 1000 mg/kg in rabbits. The I.V. LD50 is 148 mg/kg in mice, 104 mg/kg in rats, and 46 mg/kg in rabbits.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Cytotoxic T-lymphocyte protein 4
Gene symbol: CTLA4
UniProt: P16410
rs231775 Not AvailableA AlleleGingival overgrowth, periodontal disease18021981
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Cyclosporine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Cyclosporine can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe metabolism of Cyclosporine can be decreased when combined with 2-mercaptobenzothiazole.Vet Approved
3,4-DichloroisocoumarinThe serum concentration of Cyclosporine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Cyclosporine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Cyclosporine.Approved
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Cyclosporine.Approved
AceclofenacAceclofenac may increase the nephrotoxic activities of Cyclosporine.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Cyclosporine.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Cyclosporine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Cyclosporine.Approved
AcetazolamideThe serum concentration of Cyclosporine can be increased when it is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneAcetovanillone may increase the nephrotoxic activities of Cyclosporine.Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Cyclosporine.Approved, Vet Approved
AclarubicinAclarubicin may increase the nephrotoxic activities of Cyclosporine.Investigational
AdalimumabThe serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.Approved
AdapaleneAdapalene may increase the nephrotoxic activities of Cyclosporine.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Cyclosporine.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Cyclosporine.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Cyclosporine.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Cyclosporine.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Cyclosporine.Experimental
AlectinibThe serum concentration of Cyclosporine can be increased when it is combined with Alectinib.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Cyclosporine.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Cyclosporine.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Cyclosporine.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Cyclosporine.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Cyclosporine.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Cyclosporine.Approved, Investigational
AlogliptinThe serum concentration of Cyclosporine can be increased when it is combined with Alogliptin.Approved
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Cyclosporine.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Cyclosporine.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Cyclosporine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Cyclosporine.Approved, Illicit, Investigational
ALT-110The risk or severity of adverse effects can be increased when Cyclosporine is combined with ALT-110.Investigational
AmantadineThe serum concentration of Cyclosporine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Cyclosporine.Approved, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Cyclosporine.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Cyclosporine.Approved
AmikacinAmikacin may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
AmilorideAmiloride may increase the hyperkalemic activities of Cyclosporine.Approved
Aminohippuric acidThe serum concentration of Cyclosporine can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Cyclosporine.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Cyclosporine.Approved
AmiodaroneThe metabolism of Cyclosporine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Cyclosporine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Amlodipine.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Cyclosporine.Approved
AmobarbitalThe metabolism of Cyclosporine can be increased when combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Cyclosporine.Approved
AmorolfineThe metabolism of Cyclosporine can be decreased when combined with Amorolfine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Cyclosporine.Approved, Investigational
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
AmprenavirThe serum concentration of Cyclosporine can be increased when it is combined with Amprenavir.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Cyclosporine.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Amrinone.Approved
AmrubicinAmrubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
AmsacrineThe serum concentration of Cyclosporine can be increased when it is combined with Amsacrine.Approved
AN2690The metabolism of Cyclosporine can be decreased when combined with AN2690.Investigational
AnidulafunginThe metabolism of Cyclosporine can be decreased when combined with Anidulafungin.Approved, Investigational
AnisodamineAnisodamine may increase the nephrotoxic activities of Cyclosporine.Investigational
annamycinannamycin may increase the nephrotoxic activities of Cyclosporine.Investigational
AntipyrineAntipyrine may increase the nephrotoxic activities of Cyclosporine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Cyclosporine.Approved
Antithrombin III humanThe serum concentration of Cyclosporine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Cyclosporine can be increased when it is combined with Apixaban.Approved
ApramycinApramycin may increase the nephrotoxic activities of Cyclosporine.Experimental, Vet Approved
ApremilastApremilast may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
ApremilastThe metabolism of Apremilast can be decreased when combined with Cyclosporine.Approved, Investigational
AprepitantThe serum concentration of Cyclosporine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Cyclosporine can be increased when it is combined with Aprotinin.Approved, Withdrawn
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Cyclosporine.Experimental
ArbekacinArbekacin may increase the nephrotoxic activities of Cyclosporine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Cyclosporine.Approved, Investigational
ArgatrobanThe serum concentration of Cyclosporine can be increased when it is combined with Argatroban.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Cyclosporine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Cyclosporine.Approved, Investigational
ArmodafinilThe serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cyclosporine.Approved, Investigational
ArtemetherThe metabolism of Cyclosporine can be decreased when combined with Artemether.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Cyclosporine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Cyclosporine.Approved, Withdrawn
AsunaprevirThe serum concentration of Cyclosporine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Cyclosporine can be increased when it is combined with Atazanavir.Approved, Investigational
AtazanavirThe metabolism of Cyclosporine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Cyclosporine.Approved
AtomoxetineThe metabolism of Cyclosporine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Cyclosporine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Cyclosporine.Approved
Atracurium besylateCyclosporine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Cyclosporine.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Cyclosporine.Approved, Investigational
AzapropazoneAzapropazone may increase the nephrotoxic activities of Cyclosporine.Withdrawn
AzelastineAzelastine may increase the nephrotoxic activities of Cyclosporine.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Cyclosporine.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Azelnidipine.Approved
Azilsartan medoxomilAzilsartan medoxomil may increase the hyperkalemic activities of Cyclosporine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Azimilide.Investigational
AzithromycinThe metabolism of Cyclosporine can be decreased when combined with Azithromycin.Approved
Bafilomycin A1The metabolism of Cyclosporine can be decreased when combined with Bafilomycin A1.Experimental
BalsalazideBalsalazide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Cyclosporine.Investigational
BarbexacloneThe metabolism of Cyclosporine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Cyclosporine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Barnidipine.Approved
BatimastatThe serum concentration of Cyclosporine can be increased when it is combined with Batimastat.Experimental
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Cyclosporine.Investigational
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Cyclosporine.Approved
BenazeprilThe serum concentration of Cyclosporine can be increased when it is combined with Benazepril.Approved, Investigational
BenidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Benidipine.Approved
BenoxaprofenBenoxaprofen may increase the nephrotoxic activities of Cyclosporine.Withdrawn
BenzamidineThe serum concentration of Cyclosporine can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Cyclosporine can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe metabolism of Cyclosporine can be decreased when combined with Benzoic Acid.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Cyclosporine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Cyclosporine.Approved
BepridilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Cyclosporine.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the nephrotoxic activities of Cyclosporine.Investigational
BexaroteneThe serum concentration of Cyclosporine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateCyclosporine may increase the nephrotoxic activities of Bezafibrate.Approved
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Cyclosporine.Approved
Bi201335The serum concentration of Cyclosporine can be increased when it is combined with Bi201335.Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Cyclosporine.Approved
BifonazoleThe metabolism of Cyclosporine can be decreased when combined with Bifonazole.Approved
BiperidenThe serum concentration of Cyclosporine can be increased when it is combined with Biperiden.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Cyclosporine.Approved
BivalirudinThe serum concentration of Cyclosporine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Cyclosporine can be decreased when combined with Boceprevir.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Cyclosporine.Approved
BortezomibThe metabolism of Cyclosporine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Cyclosporine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cyclosporine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cyclosporine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Cyclosporine.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Cyclosporine.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Cyclosporine.Approved, Illicit
BromfenacBromfenac may increase the nephrotoxic activities of Cyclosporine.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Cyclosporine.Approved, Investigational
BromocriptineThe serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Cyclosporine.Approved
BucillamineBucillamine may increase the nephrotoxic activities of Cyclosporine.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Cyclosporine.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Cyclosporine.Approved
BumetanideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Cyclosporine.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Cyclosporine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Cyclosporine.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Cyclosporine.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Cyclosporine.Approved, Investigational
ButenafineThe metabolism of Cyclosporine can be decreased when combined with Butenafine.Approved
ButoconazoleThe metabolism of Cyclosporine can be decreased when combined with Butoconazole.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Cyclosporine.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Cyclosporine.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Cyclosporine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Cyclosporine.Approved
CaiThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cai.Investigational
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Cyclosporine.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Cyclosporine.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Cyclosporine.Approved
CandesartanThe serum concentration of Cyclosporine can be increased when it is combined with Candesartan.Approved
CandesartanCandesartan may increase the hyperkalemic activities of Cyclosporine.Approved
CandicidinThe metabolism of Cyclosporine can be decreased when combined with Candicidin.Withdrawn
CandoxatrilThe serum concentration of Cyclosporine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Cyclosporine can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Cyclosporine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Cyclosporine can be increased when combined with Carbamazepine.Approved, Investigational
CarbamazepineThe serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Cyclosporine.Approved
CarbomycinThe metabolism of Cyclosporine can be decreased when combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Cyclosporine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Cyclosporine.Approved
CarprofenCarprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.Approved
CaspofunginThe serum concentration of Cyclosporine can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may increase the nephrotoxic activities of Cyclosporine.Experimental
CDX-110The risk or severity of adverse effects can be increased when Cyclosporine is combined with CDX-110.Investigational
CelecoxibCelecoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Cyclosporine.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Cyclosporine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Cyclosporine.Approved, Vet Approved
CeritinibThe serum concentration of Cyclosporine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Cyclosporine.Withdrawn
CeruleninThe metabolism of Cyclosporine can be decreased when combined with Cerulenin.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Cyclosporine.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Cyclosporine.Approved
ChloramphenicolThe serum concentration of Cyclosporine can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Cyclosporine.Approved, Illicit
ChloroquineChloroquine may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Cyclosporine.Approved, Vet Approved
ChloroxineThe metabolism of Cyclosporine can be decreased when combined with Chloroxine.Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Cyclosporine.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Cyclosporine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Cyclosporine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Cyclosporine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Cyclosporine.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Cyclosporine.Approved, Nutraceutical
CholesterolThe serum concentration of Cyclosporine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidCyclosporine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
ChymostatinThe serum concentration of Cyclosporine can be increased when it is combined with Chymostatin.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Cyclosporine.Approved, Investigational
CiclopiroxThe metabolism of Cyclosporine can be decreased when combined with Ciclopirox.Approved, Investigational
CilastatinThe serum concentration of Cyclosporine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Cyclosporine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Cyclosporine.Approved
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Cyclosporine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Cyclosporine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cinnarizine.Approved
CiprofibrateCyclosporine may increase the nephrotoxic activities of Ciprofibrate.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Cyclosporine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cyclosporine.Approved, Investigational, Withdrawn
Cisatracurium besylateCyclosporine may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Cyclosporine.Approved
CitalopramThe metabolism of Citalopram can be decreased when combined with Cyclosporine.Approved
ClarithromycinThe metabolism of Cyclosporine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Cyclosporine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Clevidipine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Cyclosporine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Cyclosporine.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Cyclosporine.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Cyclosporine.Approved, Investigational
ClofibrateCyclosporine may increase the nephrotoxic activities of Clofibrate.Approved
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Cyclosporine.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Cyclosporine.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Cyclosporine.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Cyclosporine.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Cyclosporine.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Cyclosporine.Approved
ClonixinClonixin may increase the nephrotoxic activities of Cyclosporine.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Cyclosporine.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Cyclosporine.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Cyclosporine.Approved, Illicit
ClotrimazoleThe metabolism of Cyclosporine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Cyclosporine.Approved
CobicistatThe metabolism of Cyclosporine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Cyclosporine.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Cyclosporine.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Cyclosporine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cyclosporine.Approved
ColesevelamThe serum concentration of Cyclosporine can be decreased when it is combined with Colesevelam.Approved
ColforsinThe serum concentration of Cyclosporine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Cyclosporine.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Cyclosporine.Approved
CordycepinThe metabolism of Cyclosporine can be decreased when combined with Cordycepin.Investigational
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Cyclosporine.Approved
CrizotinibThe serum concentration of Cyclosporine can be increased when it is combined with Crizotinib.Approved
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Cyclosporine.Approved
CurcuminCurcumin may increase the nephrotoxic activities of Cyclosporine.Investigational
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Cyclosporine.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the immunosuppressive activities of Cyclosporine.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Cyclosporine.Approved, Investigational
D-LimoneneD-Limonene may increase the nephrotoxic activities of Cyclosporine.Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cyclosporine.Approved
Dabigatran etexilateThe serum concentration of Cyclosporine can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Cyclosporine.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Cyclosporine.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Cyclosporine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Cyclosporine.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Cyclosporine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Cyclosporine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Cyclosporine.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Darodipine.Experimental
DarunavirThe serum concentration of Cyclosporine can be increased when it is combined with Darunavir.Approved
DarunavirThe metabolism of Cyclosporine can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Cyclosporine can be increased when it is combined with Dasabuvir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Cyclosporine.Approved
DasatinibThe serum concentration of Cyclosporine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinDaunorubicin may increase the nephrotoxic activities of Cyclosporine.Approved
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Cyclosporine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Cyclosporine.Approved
DecamethoniumCyclosporine may increase the neuromuscular blocking activities of Decamethonium.Approved
Decanoic AcidThe metabolism of Cyclosporine can be decreased when combined with Decanoic Acid.Experimental
DeferasiroxThe serum concentration of Cyclosporine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Cyclosporine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cyclosporine.Approved
DesipramineThe serum concentration of Cyclosporine can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Cyclosporine can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.Approved
DexamethasoneThe serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Cyclosporine.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Cyclosporine.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Cyclosporine.Approved, Illicit, Vet Approved
DiclofenacDiclofenac may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Cyclosporine.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Cyclosporine.Approved
DidanosineDidanosine can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cyclosporine.Approved
DiflunisalDiflunisal may increase the nephrotoxic activities of Cyclosporine.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Cyclosporine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Cyclosporine.Approved
DigoxinThe metabolism of Digoxin can be decreased when combined with Cyclosporine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Cyclosporine.Approved, Illicit
DihydroergotamineThe metabolism of Cyclosporine can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinDihydrostreptomycin may increase the nephrotoxic activities of Cyclosporine.Vet Approved
DihydrotestosteroneDihydrotestosterone may increase the hepatotoxic activities of Cyclosporine.Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Cyclosporine.Illicit
DiltiazemThe metabolism of Cyclosporine can be decreased when combined with Diltiazem.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Cyclosporine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Cyclosporine.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Cyclosporine.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Cyclosporine.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Cyclosporine.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Cyclosporine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Cyclosporine.Approved
Domoic AcidCyclosporine may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Cyclosporine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Cyclosporine.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Cyclosporine.Approved
DotarizineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Dotarizine.Investigational
Doxacurium chlorideCyclosporine may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinThe serum concentration of Cyclosporine can be increased when it is combined with Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Cyclosporine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cyclosporine.Approved, Investigational
DoxorubicinDoxorubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Cyclosporine.Approved, Investigational
DoxycyclineThe metabolism of Cyclosporine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Cyclosporine.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.Approved
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Cyclosporine.Approved
DroxicamDroxicam may increase the nephrotoxic activities of Cyclosporine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Cyclosporine.Approved, Investigational
DuvelisibDuvelisib may increase the nephrotoxic activities of Cyclosporine.Investigational
E6201E6201 may increase the nephrotoxic activities of Cyclosporine.Investigational
EbselenEbselen may increase the nephrotoxic activities of Cyclosporine.Investigational
EcabetThe serum concentration of Cyclosporine can be increased when it is combined with Ecabet.Approved, Investigational
EconazoleThe metabolism of Cyclosporine can be decreased when combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cyclosporine.Approved
EfavirenzThe serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe metabolism of Cyclosporine can be decreased when combined with Efinaconazole.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Efonidipine.Approved
ElafinThe serum concentration of Cyclosporine can be increased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Cyclosporine can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Cyclosporine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Cyclosporine.Approved
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Cyclosporine.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Cyclosporine.Approved
EnalaprilThe serum concentration of Cyclosporine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Cyclosporine.Approved, Vet Approved
EnalaprilatThe serum concentration of Cyclosporine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Cyclosporine can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Eperisone.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Cyclosporine.Approved, Investigational
EpirizoleEpirizole may increase the nephrotoxic activities of Cyclosporine.Approved
EpirubicinEpirubicin may increase the nephrotoxic activities of Cyclosporine.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Cyclosporine.Approved
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Cyclosporine.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Cyclosporine.Approved
EprosartanEprosartan may increase the hyperkalemic activities of Cyclosporine.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Cyclosporine.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Cyclosporine.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Cyclosporine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Cyclosporine.Approved, Investigational
ErythromycinThe metabolism of Cyclosporine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Cyclosporine.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Cyclosporine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Cyclosporine.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Cyclosporine.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Cyclosporine.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Cyclosporine.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Cyclosporine.Approved, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Cyclosporine.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Cyclosporine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Cyclosporine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.Approved
EtanerceptEtanercept may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
EthanolThe metabolism of Ethanol can be decreased when combined with Cyclosporine.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Cyclosporine.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Cyclosporine.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Cyclosporine.Approved, Illicit
EtodolacEtodolac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the nephrotoxic activities of Cyclosporine.Approved
EtofibrateCyclosporine may increase the nephrotoxic activities of Etofibrate.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Cyclosporine.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Cyclosporine.Approved
EtoricoxibEtoricoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Cyclosporine.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Cyclosporine.Approved
Evening primrose oilEvening primrose oil may increase the nephrotoxic activities of Cyclosporine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cyclosporine.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Cyclosporine.Approved, Investigational
exisulindexisulind may increase the nephrotoxic activities of Cyclosporine.Investigational
EzetimibeThe serum concentration of Cyclosporine can be increased when it is combined with Ezetimibe.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Cyclosporine.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Cyclosporine.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Cyclosporine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Felodipine.Approved, Investigational
FelodipineThe metabolism of Felodipine can be decreased when combined with Cyclosporine.Approved, Investigational
FenbufenFenbufen may increase the nephrotoxic activities of Cyclosporine.Approved
FendilineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fendiline.Withdrawn
FenofibrateCyclosporine may increase the nephrotoxic activities of Fenofibrate.Approved
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Cyclosporine.Approved
FenoprofenFenoprofen may increase the nephrotoxic activities of Cyclosporine.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Cyclosporine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cyclosporine.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Cyclosporine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Cyclosporine.Approved
FimasartanThe serum concentration of Fimasartan can be increased when it is combined with Cyclosporine.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Cyclosporine.Approved
FingolimodCyclosporine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Cyclosporine.Approved
FloctafenineFloctafenine may increase the nephrotoxic activities of Cyclosporine.Approved, Withdrawn
FluconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Fluconazole.Approved
FluconazoleThe metabolism of Cyclosporine can be decreased when combined with Fluconazole.Approved
FlucytosineThe metabolism of Cyclosporine can be decreased when combined with Flucytosine.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Flunarizine.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Cyclosporine.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Cyclosporine.Approved, Illicit
FlunixinFlunixin may increase the nephrotoxic activities of Cyclosporine.Vet Approved
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Cyclosporine.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Cyclosporine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hepatotoxic activities of Cyclosporine.Approved, Illicit
FlupentixolThe serum concentration of Cyclosporine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Cyclosporine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Cyclosporine.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Cyclosporine.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Cyclosporine.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Cyclosporine.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Cyclosporine.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Cyclosporine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Cyclosporine.Approved
FluvoxamineThe metabolism of Cyclosporine can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanForasartan may increase the hyperkalemic activities of Cyclosporine.Experimental
FormoterolThe metabolism of Formoterol can be decreased when combined with Cyclosporine.Approved, Investigational
FosamprenavirThe serum concentration of Cyclosporine can be increased when it is combined with Fosamprenavir.Approved
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Cyclosporine.Approved
FosaprepitantThe serum concentration of Cyclosporine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the nephrotoxic activities of Cyclosporine.Approved
FosinoprilThe serum concentration of Cyclosporine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Cyclosporine can be decreased when it is combined with Fosphenytoin.Approved
FramycetinFramycetin may increase the nephrotoxic activities of Cyclosporine.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Cyclosporine.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Cyclosporine can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Cyclosporine is combined with G17DT.Investigational
GabapentinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Gabapentin.Approved, Investigational
GabexateThe serum concentration of Cyclosporine can be increased when it is combined with Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Cyclosporine.Approved
Gallamine TriethiodideCyclosporine may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GallopamilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Gallopamil.Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Cyclosporine.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Cyclosporine.Approved, Investigational
GeldanamycinThe serum concentration of Cyclosporine can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Cyclosporine.Approved
GemfibrozilCyclosporine may increase the nephrotoxic activities of Gemfibrozil.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Cyclosporine.Approved
GeneticinGeneticin may increase the nephrotoxic activities of Cyclosporine.Experimental
GenisteinThe serum concentration of Cyclosporine can be increased when it is combined with Genistein.Investigational
GentamicinGentamicin may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the nephrotoxic activities of Cyclosporine.Experimental
GI-5005The risk or severity of adverse effects can be increased when Cyclosporine is combined with GI-5005.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Cyclosporine.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Cyclosporine.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Cyclosporine.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclosporine.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Cyclosporine.Approved
GlycerolThe serum concentration of Cyclosporine can be increased when it is combined with Glycerol.Experimental
GlyphosateThe metabolism of Cyclosporine can be decreased when combined with Glyphosate.Experimental
GM6001The serum concentration of Cyclosporine can be increased when it is combined with GM6001.Experimental
Gramicidin DThe serum concentration of Cyclosporine can be increased when it is combined with Gramicidin D.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Cyclosporine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Cyclosporine.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Cyclosporine.Withdrawn
GriseofulvinThe serum concentration of Cyclosporine can be decreased when it is combined with Griseofulvin.Approved, Vet Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Cyclosporine.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Cyclosporine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Cyclosporine.Approved
HaloproginThe metabolism of Cyclosporine can be decreased when combined with Haloprogin.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Cyclosporine.Approved, Vet Approved
HexetidineThe metabolism of Cyclosporine can be decreased when combined with Hexetidine.Approved
HexobarbitalThe metabolism of Cyclosporine can be increased when combined with Hexobarbital.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Cyclosporine.Approved
HigenamineHigenamine may increase the nephrotoxic activities of Cyclosporine.Investigational
HirulogThe serum concentration of Cyclosporine can be increased when it is combined with Hirulog.Experimental
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Cyclosporine.Approved
HMPL-004HMPL-004 may increase the nephrotoxic activities of Cyclosporine.Investigational
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Cyclosporine.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Cyclosporine.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Cyclosporine.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Cyclosporine.Approved
Hygromycin BHygromycin B may increase the nephrotoxic activities of Cyclosporine.Vet Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Cyclosporine.Approved
IbuprofenIbuprofen may increase the nephrotoxic activities of Cyclosporine.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Cyclosporine.Approved
IbuproxamIbuproxam may increase the nephrotoxic activities of Cyclosporine.Withdrawn
IcatibantIcatibant may increase the nephrotoxic activities of Cyclosporine.Approved
IdarubicinIdarubicin may increase the nephrotoxic activities of Cyclosporine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Cyclosporine.Approved
IdelalisibThe serum concentration of Cyclosporine can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Cyclosporine can be increased when it is combined with idraparinux.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Cyclosporine resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Cyclosporine.Approved
ImatinibThe serum concentration of Cyclosporine can be increased when it is combined with Imatinib.Approved
ImidaprilThe serum concentration of Cyclosporine can be increased when it is combined with Imidapril.Investigational
ImipenemCyclosporine may increase the neurotoxic activities of Imipenem.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Cyclosporine.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Cyclosporine.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Cyclosporine.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Cyclosporine.Approved
IndinavirThe serum concentration of Cyclosporine can be increased when it is combined with Indinavir.Approved
IndinavirThe metabolism of Cyclosporine can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Cyclosporine.Investigational
IndomethacinIndomethacin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Cyclosporine.Approved, Investigational
IndoprofenIndoprofen may increase the nephrotoxic activities of Cyclosporine.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Cyclosporine is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Cyclosporine is combined with INGN 225.Investigational
INNO-206INNO-206 may increase the nephrotoxic activities of Cyclosporine.Investigational
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Cyclosporine.Approved
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Cyclosporine.Approved, Investigational
IrbesartanIrbesartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Cyclosporine.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Cyclosporine.Approved, Investigational
IsoconazoleThe metabolism of Cyclosporine can be decreased when combined with Isoconazole.Approved
IsoflurophateThe serum concentration of Cyclosporine can be increased when it is combined with Isoflurophate.Approved, Withdrawn
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Cyclosporine.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Cyclosporine.Approved
IsoxicamIsoxicam may increase the nephrotoxic activities of Cyclosporine.Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Isradipine.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Cyclosporine.Approved
ItraconazoleThe metabolism of Cyclosporine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Cyclosporine.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Cyclosporine.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Cyclosporine.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Cyclosporine.Approved, Investigational
IxazomibThe serum concentration of Cyclosporine can be increased when it is combined with Ixazomib.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Cyclosporine.Approved
JosamycinThe metabolism of Cyclosporine can be decreased when combined with Josamycin.Approved
KanamycinKanamycin may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
KebuzoneKebuzone may increase the nephrotoxic activities of Cyclosporine.Experimental
KetamineThe metabolism of Ketamine can be decreased when combined with Cyclosporine.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Cyclosporine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Cyclosporine.Approved
KetoconazoleThe metabolism of Cyclosporine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Cyclosporine.Approved, Vet Approved
KetorolacKetorolac may increase the nephrotoxic activities of Cyclosporine.Approved
KitasamycinThe metabolism of Cyclosporine can be decreased when combined with Kitasamycin.Experimental
LacidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Cyclosporine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lamotrigine.Approved, Investigational
LanreotideThe serum concentration of Cyclosporine can be decreased when it is combined with Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Cyclosporine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Cyclosporine.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Cyclosporine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Cyclosporine.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Leflunomide.Approved, Investigational
LeflunomideLeflunomide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Cyclosporine.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Cyclosporine.Approved
LepirudinThe serum concentration of Cyclosporine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe serum concentration of Cyclosporine can be increased when it is combined with Lercanidipine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lercanidipine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Cyclosporine.Approved
LetrozoleThe metabolism of Letrozole can be decreased when combined with Cyclosporine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Cyclosporine.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Cyclosporine.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Cyclosporine.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Cyclosporine.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Cyclosporine.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Cyclosporine.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Cyclosporine.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Cyclosporine.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Cyclosporine.Approved, Vet Approved
LinagliptinThe serum concentration of Cyclosporine can be increased when it is combined with Linagliptin.Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Cyclosporine.Approved
LiothyronineThe serum concentration of Cyclosporine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Cyclosporine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Cyclosporine can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the nephrotoxic activities of Cyclosporine.Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Cyclosporine.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Cyclosporine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Cyclosporine.Approved
LopinavirThe serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.Approved
LopinavirThe metabolism of Cyclosporine can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Cyclosporine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Cyclosporine.Approved
LornoxicamLornoxicam may increase the nephrotoxic activities of Cyclosporine.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Cyclosporine.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Cyclosporine.Approved
LosartanLosartan may increase the hyperkalemic activities of Cyclosporine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Cyclosporine.Approved, Investigational
LovastatinThe metabolism of Cyclosporine can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may increase the nephrotoxic activities of Cyclosporine.Approved
LuliconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Cyclosporine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Cyclosporine.Approved
LumiracoxibLumiracoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Cyclosporine.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Cyclosporine.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Cyclosporine.Approved
Magnesium salicylateMagnesium salicylate may increase the nephrotoxic activities of Cyclosporine.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Cyclosporine.Approved, Investigational
MaprotilineThe serum concentration of Cyclosporine can be increased when it is combined with Maprotiline.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Cyclosporine.Approved, Investigational
MasoprocolMasoprocol may increase the nephrotoxic activities of Cyclosporine.Approved
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Cyclosporine.Approved, Vet Approved
Meclofenamic acidMeclofenamic acid may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Cyclosporine.Approved, Investigational
Mefenamic acidMefenamic acid may increase the nephrotoxic activities of Cyclosporine.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Cyclosporine.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Cyclosporine.Approved
Megestrol acetateThe serum concentration of Cyclosporine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Cyclosporine.Approved, Nutraceutical, Vet Approved
MeloxicamMeloxicam may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Cyclosporine.Approved, Vet Approved
MelphalanMelphalan may increase the nephrotoxic activities of Cyclosporine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Cyclosporine.Investigational, Withdrawn
MeprobamateThe serum concentration of Cyclosporine can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the nephrotoxic activities of Cyclosporine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Cyclosporine.Approved
MetamizoleMetamizole may increase the nephrotoxic activities of Cyclosporine.Withdrawn
MethadoneThe metabolism of Methadone can be decreased when combined with Cyclosporine.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Cyclosporine.Illicit, Withdrawn
MethohexitalThe metabolism of Cyclosporine can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Cyclosporine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Cyclosporine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Cyclosporine.Approved, Vet Approved
MethylphenobarbitalThe metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.Approved, Vet Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Cyclosporine.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hepatotoxic activities of Cyclosporine.Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Cyclosporine.Approved
MetoclopramideMetoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MetocurineCyclosporine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideCyclosporine may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cyclosporine.Approved, Investigational
MetreleptinThe serum concentration of Cyclosporine can be decreased when it is combined with Metreleptin.Approved
MetrizamideMetrizamide may increase the nephrotoxic activities of Cyclosporine.Approved
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Cyclosporine.Approved
MevastatinThe metabolism of Cyclosporine can be decreased when combined with Mevastatin.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Cyclosporine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Cyclosporine.Approved
MibefradilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mibefradil.Withdrawn
MicafunginThe metabolism of Cyclosporine can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Cyclosporine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Cyclosporine.Approved, Illicit
MifepristoneThe serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe metabolism of Cyclosporine can be decreased when combined with Miltefosine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Minoxidil.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Cyclosporine.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Cyclosporine.Approved
MitomycinThe serum concentration of Cyclosporine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Cyclosporine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Cyclosporine.Approved, Investigational
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Cyclosporine.Approved, Investigational
MivacuriumCyclosporine may increase the neuromuscular blocking activities of Mivacurium.Approved
MizoribineMizoribine may increase the nephrotoxic activities of Cyclosporine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Cyclosporine.Approved
ModafinilThe serum concentration of Cyclosporine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Cyclosporine can be increased when it is combined with Moexipril.Approved
MonensinThe metabolism of Cyclosporine can be decreased when combined with Monensin.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Cyclosporine.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Cyclosporine.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Cyclosporine.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cyclosporine.Approved
MyxothiazolThe metabolism of Cyclosporine can be decreased when combined with Myxothiazol.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Cyclosporine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabumetoneNabumetone may increase the nephrotoxic activities of Cyclosporine.Approved
NadololThe serum concentration of Nadolol can be decreased when it is combined with Cyclosporine.Approved
NafamostatThe serum concentration of Cyclosporine can be increased when it is combined with Nafamostat.Investigational
NafcillinThe metabolism of Cyclosporine can be increased when combined with Nafcillin.Approved
NafcillinThe serum concentration of Cyclosporine can be decreased when it is combined with Nafcillin.Approved
NaftifineThe metabolism of Cyclosporine can be decreased when combined with Naftifine.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cyclosporine.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Cyclosporine.Approved, Vet Approved
NaltrexoneThe serum concentration of Cyclosporine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenNaproxen may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Cyclosporine.Approved, Vet Approved
NaringeninThe serum concentration of Cyclosporine can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Natalizumab.Approved, Investigational
NatamycinThe metabolism of Cyclosporine can be decreased when combined with Natamycin.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Cyclosporine.Approved, Investigational
NCX 4016The serum concentration of Cyclosporine can be increased when it is combined with NCX 4016.Investigational
NeamineNeamine may increase the nephrotoxic activities of Cyclosporine.Experimental
NefazodoneThe metabolism of Cyclosporine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Cyclosporine can be increased when it is combined with Nelfinavir.Approved
NelfinavirThe metabolism of Cyclosporine can be decreased when combined with Nelfinavir.Approved
NeomycinNeomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
NeosaxitoxinCyclosporine may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NeostigmineThe serum concentration of Cyclosporine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may increase the nephrotoxic activities of Cyclosporine.Approved
NetilmicinNetilmicin may increase the nephrotoxic activities of Cyclosporine.Approved
NetupitantThe serum concentration of Cyclosporine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cyclosporine can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nicardipine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Cyclosporine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Cyclosporine.Approved, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Cyclosporine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nifedipine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Cyclosporine.Approved
Niflumic AcidNiflumic Acid may increase the nephrotoxic activities of Cyclosporine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Niguldipine.Experimental
NilotinibThe metabolism of Nilotinib can be decreased when combined with Cyclosporine.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nilvadipine.Approved
NimesulideNimesulide may increase the nephrotoxic activities of Cyclosporine.Approved, Withdrawn
NimesulideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nimesulide.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Cyclosporine.Approved
NimodipineThe metabolism of Nimodipine can be decreased when combined with Cyclosporine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cyclosporine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nisoldipine.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Cyclosporine.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Cyclosporine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nitrendipine.Approved
NitroaspirinThe serum concentration of Cyclosporine can be increased when it is combined with Nitroaspirin.Investigational
NitroxolineThe metabolism of Cyclosporine can be decreased when combined with Nitroxoline.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Cyclosporine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Cyclosporine.Approved
NorfloxacinThe metabolism of Cyclosporine can be decreased when combined with Norfloxacin.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Cyclosporine.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Cyclosporine.Approved
NystatinThe metabolism of Cyclosporine can be decreased when combined with Nystatin.Approved, Vet Approved
OctreotideThe serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.Approved, Investigational
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Cyclosporine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Cyclosporine.Approved
OleandomycinThe metabolism of Cyclosporine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Cyclosporine.Approved
OlopatadineOlopatadine may increase the nephrotoxic activities of Cyclosporine.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Cyclosporine.Approved
OlsalazineOlsalazine may increase the nephrotoxic activities of Cyclosporine.Approved
OmapatrilatThe serum concentration of Cyclosporine can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Cyclosporine can be increased when it is combined with Ombitasvir.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Cyclosporine.Approved
OmeprazoleThe serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Cyclosporine.Approved
OrgoteinOrgotein may increase the nephrotoxic activities of Cyclosporine.Vet Approved
OrlistatThe serum concentration of Cyclosporine can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Cyclosporine.Approved
OsimertinibThe serum concentration of Cyclosporine can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Cyclosporine.Approved
OtamixabanThe serum concentration of Cyclosporine can be increased when it is combined with Otamixaban.Investigational
OxandroloneOxandrolone may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational
OxaprozinOxaprozin may increase the nephrotoxic activities of Cyclosporine.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Cyclosporine.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Cyclosporine.Approved
OxiconazoleThe metabolism of Cyclosporine can be decreased when combined with Oxiconazole.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Cyclosporine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Oxycodone.Approved, Illicit, Investigational
OxymetholoneOxymetholone may increase the hepatotoxic activities of Cyclosporine.Approved, Illicit
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may increase the nephrotoxic activities of Cyclosporine.Withdrawn
P-NitrophenolThe serum concentration of Cyclosporine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Cyclosporine.Approved, Vet Approved
pafuramidineThe metabolism of Cyclosporine can be decreased when combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Cyclosporine can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Cyclosporine can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Cyclosporine.Approved, Investigational
PancuroniumCyclosporine may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Cyclosporine.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Cyclosporine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Cyclosporine.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Cyclosporine.Approved
ParecoxibParecoxib may increase the nephrotoxic activities of Cyclosporine.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Cyclosporine.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Cyclosporine.Approved, Investigational
ParitaprevirThe serum concentration of Cyclosporine can be increased when it is combined with Paritaprevir.Approved
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Cyclosporine.Approved
ParomomycinParomomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
ParoxetineThe serum concentration of Cyclosporine can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideThe serum concentration of Cyclosporine can be decreased when it is combined with Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cyclosporine.Approved
PentamidineThe metabolism of Cyclosporine can be decreased when combined with Pentamidine.Approved
PentobarbitalThe metabolism of Cyclosporine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Cyclosporine.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Cyclosporine.Approved, Vet Approved, Withdrawn
PerhexilineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Perhexiline.Approved
PerindoprilThe serum concentration of Cyclosporine can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Cyclosporine.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Cyclosporine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Cyclosporine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Cyclosporine.Withdrawn
PhenobarbitalThe metabolism of Cyclosporine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Cyclosporine.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Cyclosporine.Approved
PhenylbutazonePhenylbutazone may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Cyclosporine.Approved, Vet Approved
PhenytoinThe metabolism of Cyclosporine can be increased when combined with Phenytoin.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Cyclosporine.Approved, Vet Approved
PhosphoramidonThe serum concentration of Cyclosporine can be increased when it is combined with Phosphoramidon.Experimental
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Cyclosporine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclosporine.Approved, Investigational
PimecrolimusPimecrolimus may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Cyclosporine.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Cyclosporine.Withdrawn
PinaveriumThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pinaverium.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Cyclosporine.Approved, Investigational
PipecuroniumCyclosporine may increase the neuromuscular blocking activities of Pipecuronium.Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Cyclosporine.Approved
PirarubicinPirarubicin may increase the nephrotoxic activities of Cyclosporine.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Piretanide.Experimental
PirfenidonePirfenidone may increase the nephrotoxic activities of Cyclosporine.Investigational
PiroxicamPiroxicam may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Cyclosporine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cyclosporine.Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Cyclosporine.Approved
Platelet Activating FactorThe serum concentration of Cyclosporine can be decreased when it is combined with Platelet Activating Factor.Experimental
PlicamycinPlicamycin may increase the nephrotoxic activities of Cyclosporine.Approved, Withdrawn
PodofiloxThe metabolism of Podofilox can be decreased when combined with Cyclosporine.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Cyclosporine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Cyclosporine.Approved
PosaconazoleThe metabolism of Cyclosporine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Cyclosporine.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Cyclosporine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Cyclosporine.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Cyclosporine.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Cyclosporine.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Cyclosporine.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Cyclosporine.Approved, Vet Approved
PrednisoloneThe serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of the active metabolites of Prednisone can be increased when Prednisone is used in combination with Cyclosporine.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Cyclosporine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Prenylamine.Withdrawn
PrimaquineThe metabolism of Primaquine can be decreased when combined with Cyclosporine.Approved
PrimidoneThe metabolism of Cyclosporine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Cyclosporine can be increased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Cyclosporine can be increased when it is combined with Probenecid.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Cyclosporine.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cyclosporine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Cyclosporine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Cyclosporine.Approved, Vet Approved
PromethazineThe serum concentration of Cyclosporine can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may increase the nephrotoxic activities of Cyclosporine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Cyclosporine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Cyclosporine.Approved, Investigational
ProtriptylineThe serum concentration of Cyclosporine can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cyclosporine.Approved
PTC299PTC299 may increase the nephrotoxic activities of Cyclosporine.Investigational
PuromycinPuromycin may increase the nephrotoxic activities of Cyclosporine.Experimental
PyrantelCyclosporine may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
PyrazinamideThe serum concentration of Cyclosporine can be increased when it is combined with Pyrazinamide.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Cyclosporine.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Cyclosporine.Approved, Illicit
QuercetinThe serum concentration of Cyclosporine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Cyclosporine.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Cyclosporine.Approved
QuinaprilThe serum concentration of Cyclosporine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Cyclosporine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Cyclosporine.Approved
QuinupristinThe serum concentration of Cyclosporine can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Cyclosporine.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Cyclosporine.Approved
RacecadotrilThe serum concentration of Cyclosporine can be increased when it is combined with Racecadotril.Investigational
RadicicolThe metabolism of Cyclosporine can be decreased when combined with Radicicol.Experimental
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Cyclosporine.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Cyclosporine.Approved, Investigational
RamiprilThe serum concentration of Cyclosporine can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Cyclosporine.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Cyclosporine.Approved, Investigational
RapacuroniumCyclosporine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Cyclosporine.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Cyclosporine.Approved
RemikirenThe serum concentration of Cyclosporine can be increased when it is combined with Remikiren.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Cyclosporine.Approved, Investigational
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Cyclosporine.Approved, Investigational
ReserpineThe serum concentration of Cyclosporine can be decreased when it is combined with Reserpine.Approved
ResveratrolResveratrol may increase the nephrotoxic activities of Cyclosporine.Experimental, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Cyclosporine.Approved
RibostamycinRibostamycin may increase the nephrotoxic activities of Cyclosporine.Approved
RifabutinThe metabolism of Cyclosporine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cyclosporine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cyclosporine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cyclosporine.Approved, Investigational
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Cyclosporine.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Cyclosporine.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Cyclosporine.Approved
RisedronateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Risedronate.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Cyclosporine.Approved, Investigational
RitonavirThe serum concentration of Cyclosporine can be increased when it is combined with Ritonavir.Approved, Investigational
RitonavirThe metabolism of Cyclosporine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Cyclosporine can be increased when it is combined with Rivaroxaban.Approved
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Cyclosporine.Approved
RocuroniumCyclosporine may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibRofecoxib may increase the nephrotoxic activities of Cyclosporine.Investigational, Withdrawn
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Cyclosporine.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Cyclosporine.Approved
RolapitantThe metabolism of Rolapitant can be decreased when combined with Cyclosporine.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Cyclosporine.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Cyclosporine.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Cyclosporine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Cyclosporine.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Cyclosporine.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Cyclosporine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Cyclosporine.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Cyclosporine.Approved, Withdrawn
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Cyclosporine.Approved
SacubitrilSacubitril may increase the hyperkalemic activities of Cyclosporine.Approved
SalicylamideSalicylamide may increase the nephrotoxic activities of Cyclosporine.Approved
Salicylhydroxamic AcidThe metabolism of Cyclosporine can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Cyclosporine can be decreased when combined with Salicylic acid.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Cyclosporine.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Cyclosporine.Approved
SalsalateSalsalate may increase the nephrotoxic activities of Cyclosporine.Approved
SaprisartanSaprisartan may increase the hyperkalemic activities of Cyclosporine.Experimental
SaquinavirThe serum concentration of Cyclosporine can be increased when it is combined with Saquinavir.Approved, Investigational
SaquinavirThe metabolism of Cyclosporine can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinSaralasin may increase the hyperkalemic activities of Cyclosporine.Investigational
SaxagliptinThe serum concentration of Cyclosporine can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Cyclosporine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Cyclosporine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Cyclosporine.Approved
SeratrodastSeratrodast may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Cyclosporine.Approved, Investigational
SertaconazoleThe metabolism of Cyclosporine can be decreased when combined with Sertaconazole.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Cyclosporine.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Cyclosporine.Approved
SevelamerThe serum concentration of Cyclosporine can be decreased when it is combined with Sevelamer.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Cyclosporine.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Cyclosporine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Cyclosporine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cyclosporine.Approved
SiltuximabThe serum concentration of Cyclosporine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Cyclosporine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cyclosporine.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Cyclosporine.Approved
SinefunginThe metabolism of Cyclosporine can be decreased when combined with Sinefungin.Experimental
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cyclosporine.Approved, Investigational
SirolimusThe metabolism of Sirolimus can be decreased when combined with Cyclosporine.Approved, Investigational
SisomicinSisomicin may increase the nephrotoxic activities of Cyclosporine.Investigational
SitagliptinThe serum concentration of Cyclosporine can be increased when it is combined with Sitagliptin.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Cyclosporine.Approved, Investigational
SitaxentanThe serum concentration of Sitaxentan can be increased when it is combined with Cyclosporine.Approved, Investigational, Withdrawn
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Cyclosporine.Approved, Investigational, Withdrawn
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Cyclosporine.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Cyclosporine.Approved
SolithromycinThe metabolism of Cyclosporine can be decreased when combined with Solithromycin.Investigational
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Cyclosporine.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Cyclosporine.Approved, Investigational
SP1049CSP1049C may increase the nephrotoxic activities of Cyclosporine.Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Cyclosporine.Approved
SpectinomycinSpectinomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Cyclosporine.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Cyclosporine.Approved
SpiraprilThe serum concentration of Cyclosporine can be increased when it is combined with Spirapril.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Cyclosporine.Approved
SpironolactoneThe serum concentration of Cyclosporine can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Cyclosporine is combined with SRP 299.Investigational
SRT501SRT501 may increase the nephrotoxic activities of Cyclosporine.Investigational
St. John's WortThe serum concentration of Cyclosporine can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololStanozolol may increase the hepatotoxic activities of Cyclosporine.Approved, Vet Approved
StaurosporineThe serum concentration of Cyclosporine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Cyclosporine can be increased when it is combined with Stiripentol.Approved
StreptomycinStreptomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
StreptozocinStreptozocin may increase the nephrotoxic activities of Cyclosporine.Approved
StreptozocinThe serum concentration of Cyclosporine can be decreased when it is combined with Streptozocin.Approved
SuccinylcholineCyclosporine may increase the neuromuscular blocking activities of Succinylcholine.Approved
SucralfateSucralfate can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Cyclosporine.Approved, Investigational
SulconazoleThe metabolism of Cyclosporine can be decreased when combined with Sulconazole.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Cyclosporine.Approved, Vet Approved
SulfadiazineSulfadiazine may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Cyclosporine.Approved
SulfamethoxazoleSulfamethoxazole may increase the nephrotoxic activities of Cyclosporine.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Cyclosporine.Approved
SulfasalazineSulfasalazine may increase the nephrotoxic activities of Cyclosporine.Approved
SulfinpyrazoneThe serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Cyclosporine.Approved
SulfisoxazoleThe metabolism of Cyclosporine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulfisoxazoleSulfisoxazole may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
SulindacSulindac may increase the nephrotoxic activities of Cyclosporine.Approved
SumatriptanThe serum concentration of Cyclosporine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Cyclosporine.Approved, Investigational
SuprofenSuprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Withdrawn
SuprofenThe metabolism of Suprofen can be decreased when combined with Cyclosporine.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Cyclosporine.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Cyclosporine.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Cyclosporine.Approved
TacrineThe serum concentration of Cyclosporine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Cyclosporine.Approved, Investigational
TacrolimusTacrolimus may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Cyclosporine.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Cyclosporine.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Cyclosporine.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Cyclosporine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Cyclosporine.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Cyclosporine.Approved
TasosartanTasosartan may increase the hyperkalemic activities of Cyclosporine.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Cyclosporine.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Cyclosporine.Experimental
TavaboroleThe metabolism of Cyclosporine can be decreased when combined with Tavaborole.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Cyclosporine.Approved
TelaprevirThe serum concentration of Cyclosporine can be increased when it is combined with Telaprevir.Approved
TelaprevirThe metabolism of Cyclosporine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Cyclosporine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Cyclosporine can be increased when it is combined with Telmisartan.Approved, Investigational
TelmisartanTelmisartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Cyclosporine.Approved
TemocaprilThe serum concentration of Cyclosporine can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Cyclosporine.Approved
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Cyclosporine.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Cyclosporine.Approved
TenoxicamTenoxicam may increase the nephrotoxic activities of Cyclosporine.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Cyclosporine.Approved
TepoxalinTepoxalin may increase the nephrotoxic activities of Cyclosporine.Vet Approved
TerazosinThe serum concentration of Cyclosporine can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Cyclosporine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe metabolism of Cyclosporine can be decreased when combined with Terconazole.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Cyclosporine.Withdrawn
TeriflunomideTeriflunomide may increase the nephrotoxic activities of Cyclosporine.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Cyclosporine.Investigational
TestosteroneTestosterone may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Cyclosporine.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Cyclosporine.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Cyclosporine is combined with TG4010.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Cyclosporine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Cyclosporine.Approved
ThiamylalThe metabolism of Cyclosporine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Cyclosporine.Approved, Vet Approved
ThiopentalThe metabolism of Cyclosporine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Cyclosporine.Approved
ThiorphanThe serum concentration of Cyclosporine can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Cyclosporine.Approved
ThymolThe metabolism of Cyclosporine can be decreased when combined with Thymol.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Cyclosporine.Approved
Tiaprofenic acidTiaprofenic acid may increase the nephrotoxic activities of Cyclosporine.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.Approved
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Cyclosporine.Approved
TiclopidineThe metabolism of Cyclosporine can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Cyclosporine.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Cyclosporine.Approved, Investigational
TinoridineTinoridine may increase the nephrotoxic activities of Cyclosporine.Investigational
TioconazoleThe metabolism of Cyclosporine can be decreased when combined with Tioconazole.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Cyclosporine.Approved
TipranavirThe serum concentration of Cyclosporine can be increased when it is combined with Tipranavir.Approved, Investigational
TipranavirThe metabolism of Tipranavir can be decreased when combined with Cyclosporine.Approved, Investigational
TobramycinTobramycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
TocilizumabThe serum concentration of Cyclosporine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibCyclosporine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Cyclosporine.Approved
Tolfenamic AcidTolfenamic Acid may increase the nephrotoxic activities of Cyclosporine.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tolfenamic Acid.Approved
TolmetinTolmetin may increase the nephrotoxic activities of Cyclosporine.Approved
TolnaftateThe metabolism of Cyclosporine can be decreased when combined with Tolnaftate.Approved, Vet Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Cyclosporine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cyclosporine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cyclosporine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide.Approved
TorasemideThe metabolism of Torasemide can be decreased when combined with Cyclosporine.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Cyclosporine.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Cyclosporine.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Cyclosporine.Approved, Investigational
TrandolaprilThe serum concentration of Cyclosporine can be increased when it is combined with Trandolapril.Approved
TranilastTranilast may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Cyclosporine.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Cyclosporine.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Cyclosporine.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Cyclosporine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Cyclosporine.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Cyclosporine.Approved, Vet Approved
TriamtereneTriamterene may increase the hyperkalemic activities of Cyclosporine.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Cyclosporine.Approved
TrifluoperazineThe serum concentration of Cyclosporine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Cyclosporine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Cyclosporine.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Cyclosporine.Approved, Vet Approved
TrimetrexateThe metabolism of Cyclosporine can be decreased when combined with Trimetrexate.Approved, Investigational
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Cyclosporine.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the nephrotoxic activities of Cyclosporine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Cyclosporine.Withdrawn
TroleandomycinThe metabolism of Cyclosporine can be decreased when combined with Troleandomycin.Approved
TubocurarineCyclosporine may increase the neuromuscular blocking activities of Tubocurarine.Approved
TylosinThe metabolism of Cyclosporine can be decreased when combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Cyclosporine can be increased when it is combined with Ubenimex.Experimental
UdenafilThe metabolism of Udenafil can be decreased when combined with Cyclosporine.Approved, Investigational
UlinastatinThe serum concentration of Cyclosporine can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Cyclosporine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Cyclosporine.Approved
ValdecoxibValdecoxib may increase the nephrotoxic activities of Cyclosporine.Investigational, Withdrawn
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Cyclosporine.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Cyclosporine.Approved, Investigational
ValrubicinValrubicin may increase the nephrotoxic activities of Cyclosporine.Approved
ValsartanThe metabolism of Valsartan can be decreased when combined with Cyclosporine.Approved, Investigational
ValsartanValsartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Cyclosporine.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Cyclosporine.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Cyclosporine.Approved
VecuroniumCyclosporine may increase the neuromuscular blocking activities of Vecuronium.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Cyclosporine.Approved
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Cyclosporine.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Cyclosporine.Approved
VenlafaxineThe metabolism of Cyclosporine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Cyclosporine can be decreased when combined with Verapamil.Approved
VerapamilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Cyclosporine.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Cyclosporine.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Cyclosporine.Approved
VildagliptinThe serum concentration of Cyclosporine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Cyclosporine.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Cyclosporine.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Cyclosporine.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Cyclosporine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Cyclosporine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Cyclosporine.Approved
Vitamin CThe serum concentration of Cyclosporine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
Vitamin EThe serum concentration of Cyclosporine can be decreased when it is combined with Vitamin E.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Cyclosporine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Cyclosporine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Cyclosporine.Approved
XimelagatranThe serum concentration of Cyclosporine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Cyclosporine.Approved, Investigational, Withdrawn
XylometazolineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Xylometazoline.Approved
Ym150The serum concentration of Cyclosporine can be increased when it is combined with Ym150.Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Cyclosporine.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Cyclosporine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Cyclosporine.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Cyclosporine.Approved, Illicit, Investigational
ZaltoprofenZaltoprofen may increase the nephrotoxic activities of Cyclosporine.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Cyclosporine.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Cyclosporine.Approved
ZileutonZileuton may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Withdrawn
ZileutonThe metabolism of Zileuton can be decreased when combined with Cyclosporine.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Cyclosporine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Cyclosporine can be decreased when combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Cyclosporine.Approved
ZomepiracZomepirac may increase the nephrotoxic activities of Cyclosporine.Withdrawn
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Cyclosporine.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Cyclosporine.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Cyclosporine.Approved
ZorubicinZorubicin may increase the nephrotoxic activities of Cyclosporine.Experimental
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Cyclosporine.Approved, Investigational
Food Interactions
  • Avoid salt substitutes containing potassium.
  • Avoid taking with grapefruit or grapefruit juice as grapefruit can significantly increase serum levels of this product.
  • Red wine may reduce cyclosporine levels due to increased metabolism, therefore it appears prudent to avoid red wine (white wine does not appear to affect cyclosporine metabolism).
  • When taken with a meal, AUC and Cmax of cyclosporine modified decreased.
References
Synthesis Reference

Hans Dietl, “Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production.” U.S. Patent US5527537, issued October, 1990.

US5527537
General References
  1. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30;330(26):1841-5. [PubMed:8196726 ]
  2. Husi H, Schorgendorfer K, Stempfer G, Taylor P, Walkinshaw MD: Prediction of substrate-specific pockets in cyclosporin synthetase. FEBS Lett. 1997 Sep 15;414(3):532-6. [PubMed:9323029 ]
  3. Link [Link]
External Links
ATC CodesS01XA18L04AD01
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (176 KB)
MSDSDownload (83.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8727
Blood Brain Barrier-0.9659
Caco-2 permeable-0.6994
P-glycoprotein substrateSubstrate0.8463
P-glycoprotein inhibitor IInhibitor0.8685
P-glycoprotein inhibitor IINon-inhibitor0.5992
Renal organic cation transporterNon-inhibitor0.9485
CYP450 2C9 substrateNon-substrate0.8628
CYP450 2D6 substrateNon-substrate0.8823
CYP450 3A4 substrateSubstrate0.6407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.923
CYP450 2D6 inhibitorNon-inhibitor0.9265
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.6112
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9968
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8948
BiodegradationNot ready biodegradable0.9244
Rat acute toxicity2.8788 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9815
hERG inhibition (predictor II)Non-inhibitor0.9214
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Pliva inc
  • Sandoz inc
  • Abbott laboratories
  • Novartis pharmaceuticals corp
  • Allergan inc
  • Bedford laboratories div ben venue laboratories inc
  • Pharmaforce inc
  • Novex pharma
  • Watson laboratories inc
  • Wockhardt eu operations (swiss) ag
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral25 mg/1
Capsule, gelatin coatedOral100 mg/1
Capsule, gelatin coatedOral25 mg/1
Injection, solutionIntravenous50 mg/mL
Capsule, liquid filledOral50 mg/1
CapsuleOral50 mg/1
SolutionOral100 mg/mL
CapsuleOral100 mg
CapsuleOral10 mg
CapsuleOral25 mg
CapsuleOral50 mg
SolutionOral100 mg
EmulsionOphthalmic.5 mg/mL
EmulsionOphthalmic0.05 %
Capsule, liquid filledOral100 mg/1
Capsule, liquid filledOral25 mg/1
InjectionIntravenous50 mg/mL
LiquidIntravenous50 mg
LiquidOral100 mg
Prices
Unit descriptionCostUnit
SandIMMUNE 100 mg/ml Solution 50ml Bottle499.62USD bottle
Neoral 100 mg/ml Solution 50ml Bottle346.14USD bottle
CycloSPORINE Modified 100 mg/ml Solution 50ml Bottle311.53USD bottle
SandIMMUNE 30 100 mg capsule Box308.69USD box
Restasis 30 0.05% Emulsion 1 Box = 30 Containers205.99USD box
Neoral 30 100 mg capsule Box190.54USD box
CycloSPORINE Modified 30 100 mg capsule Box171.48USD box
Gengraf 30 100 mg capsule Box159.94USD box
SandIMMUNE 30 25 mg capsule Box77.33USD box
Neoral 30 25 mg capsule Box47.69USD box
SandIMMUNE 50 mg/ml Solution 5ml Ampule46.38USD ampule
Gengraf 30 25 mg capsule Box42.99USD box
CycloSPORINE Modified 30 25 mg capsule Box42.9USD box
Cyclosporine a powder25.2USD g
Sandimmune 100 mg capsule9.89USD capsule
Sandimmune 50 mg/ml ampul7.71USD ml
Cyclosporine 100 mg capsule6.46USD capsule
Neoral 100 mg gelatn capsule6.11USD capsule
Cyclosporine 100 mg softgel5.5USD softgel capsule
Cyclosporine modif 100 mg softgel5.5USD softgel capsule
Cyclosporine modif 100 mg capsule5.49USD capsule
Cyclosporine 50 mg/ml amp5.45USD ml
Cyclosporine 50 mg/ml vial5.28USD ml
Gengraf 100 mg capsule5.28USD capsule
Restasis 0.05% eye emulsion4.49USD each
Cyclosporine 50 mg softgel2.74USD softgel capsule
Sandimmune 25 mg capsule2.48USD capsule
Cyclosporine 25 mg capsule1.56USD capsule
Neoral 25 mg gelatin capsule1.53USD capsule
Cyclosporine 25 mg softgel1.38USD softgel capsule
Gengraf 25 mg capsule1.32USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1332150 No1994-09-272011-09-27Canada
CA2108018 No2003-04-152012-04-16Canada
US4839342 No1992-08-022009-08-02Us
US5985321 No1994-09-262014-09-26Us
US8629111 No2004-08-272024-08-27Us
US8633162 No2004-08-272024-08-27Us
US8642556 No2004-08-272024-08-27Us
US8648048 No2004-08-272024-08-27Us
US8685930 No2004-08-272024-08-27Us
US9248191 No2004-08-272024-08-27Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point148-151 °CNot Available
Caco2 permeability-6.05ADME Research, USCD
Predicted Properties
PropertyValueSource
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.
KingdomOrganic compounds
Super ClassOrganic Polymers
ClassPolypeptides
Sub ClassNot Available
Direct ParentPolypeptides
Alternative Parents
Substituents
  • Polypeptide
  • Cyclosporin-backbone
  • Cyclic peptoid/peptide
  • Macrolactam
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Lactam
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
  • Non-ribosomal peptide/polyketide hybrids (C05086 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Not Available
Specific Function:
Likely involved in the mobilization of calcium as a result of the TCR/CD3 complex interaction. Binds to cyclophilin B.
Gene Name:
CAMLG
Uniprot ID:
P49069
Molecular Weight:
32952.255 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Bernasconi R, Solda T, Galli C, Pertel T, Luban J, Molinari M: Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation. PLoS One. 2010 Sep 28;5(9). pii: e13008. doi: 10.1371/journal.pone.0013008. [PubMed:20927389 ]
  4. Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. doi: 10.1016/j.ejphar.2010.07.031. Epub 2010 Aug 3. [PubMed:20674565 ]
  5. Galat A, Bua J: Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci. 2010 Oct;67(20):3467-88. doi: 10.1007/s00018-010-0437-0. Epub 2010 Jul 4. [PubMed:20602248 ]
  6. Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. doi: 10.1186/1756-9966-29-97. [PubMed:20637127 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Calcium ion binding
Specific Function:
Regulatory subunit of calcineurin, a calcium-dependent, calmodulin stimulated protein phosphatase. Confers calcium sensitivity (By similarity).
Gene Name:
PPP3R2
Uniprot ID:
Q96LZ3
Molecular Weight:
19533.065 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. doi: 10.1016/j.ejphar.2010.07.031. Epub 2010 Aug 3. [PubMed:20674565 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Virion binding
Specific Function:
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.
Gene Name:
PPIA
Uniprot ID:
P62937
Molecular Weight:
18012.42 Da
References
  1. Keckesova Z, Ylinen LM, Towers GJ: Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol. 2006 May;80(10):4683-90. [PubMed:16641261 ]
  2. Patwardhan AM, Jeske NA, Price TJ, Gamper N, Akopian AN, Hargreaves KM: The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11393-8. Epub 2006 Jul 18. [PubMed:16849427 ]
  3. Redell JB, Zhao J, Dash PK: Acutely increased cyclophilin a expression after brain injury: a role in blood-brain barrier function and tissue preservation. J Neurosci Res. 2007 Jul;85(9):1980-8. [PubMed:17461417 ]
  4. Schaller T, Ylinen LM, Webb BL, Singh S, Towers GJ: Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses. J Virol. 2007 Sep;81(18):10055-63. Epub 2007 Jul 3. [PubMed:17609268 ]
  5. Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. doi: 10.1186/1756-9966-29-97. [PubMed:20637127 ]
  6. Stegmann CM, Luhrmann R, Wahl MC: The crystal structure of PPIL1 bound to cyclosporine A suggests a binding mode for a linear epitope of the SKIP protein. PLoS One. 2010 Apr 2;5(4):e10013. doi: 10.1371/journal.pone.0010013. [PubMed:20368803 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Peptidyl-prolyl cis-trans isomerase activity
Specific Function:
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Involved in regulation of the mitochondrial permeability transition pore (mPTP). It is proposed that its association with the mPTP is masking a binding site for inhibiting inorganic phosphate (Pi) and promotes the open probability of the mPTP leading to apoptosi...
Gene Name:
PPIF
Uniprot ID:
P30405
Molecular Weight:
22040.09 Da
References
  1. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW: Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984 Nov 2;226(4674):544-7. [PubMed:6238408 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  2. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137 ]
  3. Tiberghien F, Kurome T, Takesako K, Didier A, Wenandy T, Loor F: Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter. J Med Chem. 2000 Jun 29;43(13):2547-56. [PubMed:10891114 ]
  4. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287 ]
  5. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  6. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. [PubMed:11784143 ]
  7. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  8. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945 ]
  9. Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71. [PubMed:12604693 ]
  10. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153 ]
  11. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  12. Atkinson DE, Greenwood SL, Sibley CP, Glazier JD, Fairbairn LJ: Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol. 2003 Sep;285(3):C584-91. Epub 2003 Apr 30. [PubMed:12724138 ]
  13. Hamada A, Miyano H, Watanabe H, Saito H: Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther. 2003 Nov;307(2):824-8. Epub 2003 Sep 15. [PubMed:12975485 ]
  14. Corea G, Fattorusso E, Lanzotti V, Taglialatela-Scafati O, Appendino G, Ballero M, Simon PN, Dumontet C, Di Pietro A: Modified jatrophane diterpenes as modulators of multidrug resistance from Euphorbia dendroides L. Bioorg Med Chem. 2003 Nov 17;11(23):5221-7. [PubMed:14604686 ]
  15. Rao US, Scarborough GA: Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol. 1994 Apr;45(4):773-6. [PubMed:7514263 ]
  16. Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25. [PubMed:8960059 ]
  17. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55. [PubMed:9205004 ]
  18. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363 ]
  19. Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. [PubMed:9732409 ]
  20. Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K: Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res. 1998 Nov;89(11):1220-8. [PubMed:9914792 ]
  21. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. [PubMed:10087141 ]
  22. Wigler PW: PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochem Biophys Res Commun. 1999 Apr 13;257(2):410-3. [PubMed:10198227 ]
  23. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH: Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther. 2000 Jan;292(1):310-8. [PubMed:10604964 ]
  24. Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K, Shimizu A, Miyoshi M, Takagi K, Takagi K, Hasegawa T: Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol. 2004 Jan 26;484(2-3):333-9. [PubMed:14744620 ]
  25. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D: The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release. 2004 Mar 24;95(3):447-53. [PubMed:15023456 ]
  26. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753 ]
  27. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  28. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
  29. Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300. [PubMed:19530439 ]
  30. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690 ]
  31. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  32. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  33. Seeballuck F, Ashford MB, O'Driscoll CM: The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm Res. 2003 Jul;20(7):1085-92. [PubMed:12880295 ]
  34. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  35. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 Mar 25;268(9):6077-80. [PubMed:7681059 ]
  36. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C: Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996 Aug;118(7):1841-7. [PubMed:8842452 ]
  37. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997 Sep;62(3):248-60. [PubMed:9333100 ]
  38. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ: Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999 Apr;16(4):478-85. [PubMed:10227700 ]
  39. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58. [PubMed:12404239 ]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
  3. Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. 2001 May;33(5):1223-31. [PubMed:11343252 ]
  4. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
  5. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30. [PubMed:10648470 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Pec MK, Aguirre A, Fernandez JJ, Souto ML, Dorta JF, Villar J: Dehydrothyrsiferol does not modulate multidrug resistance-associated protein 1 resistance: a functional screening system for MRP1 substrates. Int J Mol Med. 2002 Nov;10(5):605-8. [PubMed:12373300 ]
  2. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D: The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem. 1994 Nov 11;269(45):27807-10. [PubMed:7961706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Bile acid:sodium symporter activity
Specific Function:
Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Plays a key role in cholesterol metabolism.
Gene Name:
SLC10A2
Uniprot ID:
Q12908
Molecular Weight:
37713.405 Da
References
  1. Craddock AL, Love MW, Daniel RW, Kirby LC, Walters HC, Wong MH, Dawson PA: Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69. [PubMed:9458785 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. [PubMed:9486191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Sweet DH, Wolff NA, Pritchard JB: Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem. 1997 Nov 28;272(48):30088-95. [PubMed:9374486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946 ]
  2. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674 ]
  3. Kamisako T, Leier I, Cui Y, Konig J, Buchholz U, Hummel-Eisenbeiss J, Keppler D: Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999 Aug;30(2):485-90. [PubMed:10421658 ]
  4. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999 Dec;56(6):1219-28. [PubMed:10570049 ]
  5. Horikawa M, Kato Y, Tyson CA, Sugiyama Y: The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet. 2002;17(1):23-33. [PubMed:15618649 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. [PubMed:11437380 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595 ]
  2. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 2003 Feb;304(2):610-6. [PubMed:12538813 ]
  3. Nozawa T, Tamai I, Sai Y, Nezu J, Tsuji A: Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol. 2003 Jul;55(7):1013-20. [PubMed:12906759 ]
  4. Fehrenbach T, Cui Y, Faulstich H, Keppler D: Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):415-20. Epub 2003 Oct 3. [PubMed:14530907 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:39